Curcumin for the treatment of glioblastoma

Anticancer Research

Volumn 35, Issue 12, 2015, Pages 6373-6378

  Sordillo, Laura A ^a   Sordillo, Peter P ^a   Helson, Lawrence ^a  

^a SignPath Pharma Inc   (United States)

Author keywords

Blood brain barrier; Cancer stem cells; Ceramide; Combination chemotherapy; Curcumin; Glioblastoma; Lipophilic agent; Lomustine; Review

Indexed keywords

CURCUMIN; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; JANUS KINASE; LOMUSTINE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; NOTCH RECEPTOR; REACTIVE OXYGEN METABOLITE; SONIC HEDGEHOG PROTEIN; SPHINGOMYELIN PHOSPHODIESTERASE; STRESS ACTIVATED PROTEIN KINASE; TEMOZOLOMIDE; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; WNT PROTEIN;

APOPTOSIS; AUTOPHAGY; BLOOD BRAIN BARRIER; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STEM CELL; CANCER SURVIVAL; GLIOBLASTOMA; HUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; SURVIVAL TIME; TUMOR RECURRENCE; TUMOR VOLUME; WNT SIGNALING PATHWAY; COMBINATION DRUG THERAPY; MORTALITY; PROCEDURES; PROGNOSIS; SURVIVAL RATE;

BLOOD-BRAIN BARRIER; CURCUMIN; DRUG THERAPY, COMBINATION; GLIOBLASTOMA; HUMANS; PROGNOSIS; SURVIVAL RATE;

EID: 84949439203     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. Virk SM, Gibson RM, Quinones-Mateu ME and Barnholtz-Sloan JS: Identification of variants in primary and recurrent glioblastoma using a cancer-specific gene panel and whole exome sequencing. PLos ONE 10(5): e0124174, 2015.
2. Tang C, Guo J, Chen H, Yao C, Zhuang D, Wang Y, Tang W, Ren G, Wu J, Mao Y and Zhou L: Gene mutation profiling of primary glioblastoma through multiple tumor biopsy guided by 1Hmagnetic resonance spectroscopy. Int J Clin Exp Pathol 8(5): 5327-5335, 2015.
3. Taylor T, Fumari F and Cavenee W: Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance. Curr Cancer Drug Targets 12(3): 197-209, 2012.
4. Arif SH, Pandith AA, Bhat AR, Ramzan AU, Malik NK, Chibber SS, Wani AA, Tabasum R and Kirmani A: EGFR and PTEN gene mutation status in glioblastoma patients and their prognostic impact on patient's survival. J Carcinog Mutagen 6:218, 2015.
5. American Brain Tumor Association. http://www.abta.org/braintumor-information/types-of-tumors/glioblastoma.html
6. National Brain Tumor Society. http://braintumor.org/brain-tumorinformation/understanding-brain-tumors/tumor-types/
7. Shahar T, Nossek E, Steinberg DM, Rozovski U, Blumenthal DT, Bokstein F, Sitt R, Freedman S, Corn BW, Kanner AA, Ram Z: The impact of enrollment in clinical trials on survival of patients with glioblastoma. J Clin Neurosci 19: 1530-1534, 2012.
8. Park JK, Hodges T, Arko L, Shen M, Iacono DD, McNabb A, Bailey NO, Kreisl TN, Iwamoto FM, Sul J, Auh S, Park GE, Fine HA, Black PM: Scale to predict survival after surgery for recurrent glioblastoma multiforme. J Clinical Oncology 28(24): 3838-3843, 2010.
9. Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, Raza SM, Pascual-Gallego M, Ibrahim A, Hernandez-Hermann M, Gomez L, Ye X, Weingart JD, Olivi A, Blakeley J, Gallia GL, Lim M, Brem H and Quinones-Hinojosa A: Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro Oncol 16: 113-122, 2013.
10. McGirt MJ, Mukherjee D, Chaichana KL, Than KD, Weingart JD and Quinones-Hinojosa A: Association of surgically acquired motor and language deficits on overall survival after resection of glioblastoma multiforme. Neurosurgery 65(3): 463-469; discussion 469-470, 2009.
11. Brown PD, Maurer MJ, Rummans TA, Pollock BE, Ballman KV, Sloan JA, Boeve BF, Arusell RM, Clark MM, Buckner JC: A prospective study of quality of life in adults with newly diagnosed high-grade gliomas: the impact of the extent of resection on quality of life and survival. Neurosurgery 57(3): 495-504, 2005.
12. Mason WP and Cairncross JG: Drug insight: temozolomide as a treatment for malignant glioma-impact of a recent trial. Nat Clin Pract Neurol 1: 88-95, 2005.
13. Nagasawa DT, Chow F, Yew A, Kim W, Cremer N and Yang I: Temozolomide and other potential agents for the treatment of glioblastoma multiforme. Neurosurg Clin N Am 23: 307-322, 2012.
14. Cohen MH, Johnson JR and Pazdur R: Food and drug administration drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. Clin Cancer Res 11: 6767-6771, 2005.
15. Rosso L, Brock CS, Gallo JM, Saleem A, Price PM, Turkheimer FE and Aboagye EO: A new model for prediction of drug distribution in tumor and normal tissues: Pharmacokinetics of temozolomide in glioma patients. Cancer Res 69: 120-127, 2009.
16. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Eng J Med 352: 987-996, 2005.
17. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG and Mirimanoff RO: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5): 459-466, 2009.
18. Darefsky AS, King JT Jr. And Dubrow R. Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of surveillance, epidemiology, and end results registries. Cancer 118: 2163-2172, 2011.
19. Lund EL, Spang-Thomsen M, Skovgaard-Poulsen H and Kristjansen PE: Tumor angiogenesis - A new therapeutic target in gliomas. Acta Neurol Scand 97: 52-62, 1998.
20. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG and Batchelor TT: Angiogenesis in brain tumours. Nat Rev Neurosci 8: 610-622, 2007.
21. Taal W, OOsterkamp H, Walenkamp AM, Dubbink HJ, Beerepoot LV, Hanse MC, Buter J, Honkoop AH, Boerman D, de Vos FY, Dinjens WN, Enting RH, Taphoorn MJ, van den Berkmortel FW, Jansen RL, Brandsma D, Bromberg JE, van Heuvel I, Vernhout RM, van der Holt B and van den Bent MJ: Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase II trial. Lancet Oncology 15: 943-953, 2014.
22. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ Jr. And Mehta MP: A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370: 699-708, 2014.
23. Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L and Cloughesy T: Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370: 709-722, 2014.
24. Schabel FM Jr: Nitrosoureas: a review of experimental antitumor activity. Cancer Treat Rep 60(6): 665-698, 1976.
25. Agarwal S, Chadha D and Mehrotra R: Molecular modeling and spectroscopic studies of semustine binding with DNA and its comparison with lomustine-DNA adduct formation. J Biomol Struct Dyn 33(8): 1653-1668, 2015.
26. Patel MA, Kim JE, Ruzevick J, Li G and Lim M: The future of glioblastoma therapy: synergism of standard of care and immunotherapy. Cancers 6: 1953-1985, 2014.
27. Meng B, Li J and Cao H: Antioxidant and antiinflammatory activities of curcumin on diabetes mellitus and its complications. Curr Pharm Des 19(11): 2101-2113, 2013.
28. Mishra A and Palanivelu K: The effect of curcumin (turmeric) on Alzheimer's disease: an overview. Ann Indian Acad Neurol 11(1): 13-19, 2008.
29. Anggakusma, Colpitts CC, Schang LM, Rachmawati H, Frentzen A, Pfaender A, Behrendt A, Behrendt P, Brown RJ, Bankwitz D, Steinmann J, Ott M, Meuleman P, Rice CM, Ploss A, Pieschmann T and Steinmann E: Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells. Gut 63(7): 1137:1149, 2014.
30. Chandran B and Goel A: A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis. Phytother Res 26(11): 1719:1725, 2012.
31. Wahlstrom B and Blennow G: A study on the fate of curcumin in the rat. Acta Pharmacol Toxicol (Copenh) 43: 86-92, 1978.
32. Storka A, Vcelar B, Klickovic U, Gouya G, Weisshaar S, Aschauer S, Bolger G, Helson L and Wolzt M: Safety, tolerability and pharmacokinetics of liposomal curcumin in healthy humans. Int J Clin Pharmacol Ther 53(1): 54-65, 2015.
33. Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, Marczylo TH, Morgan B, Hemingway D, Plummer SM, Pirmohamed M, Gescher AJ and Steward WP: Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 10: 6847-6854, 2004.
34. Aggarwal BB, Kumar A and Bharti AC: Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 23(1A): 363-398, 2003.
35. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, Jee SH, Chen GS, Chen TM, Chen CA, Lai MK, Pu YS, Pan MH, Wang YJ, Tsai CC and Hsieh CY: Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 21(4B): 2895-2900, 2001.
36. Sordillo PP and Helson L: Suppression of cytokine release and cytokine storm: a potential therapy for patients with Ebola and other viral infections. In Vivo 29: 1-4, 2015.
37. Chan MM: Inhibition of tumor necrosis factor by curcumin, a phytochemical. Biochem Pharmacol 49: 1551-1556, 1995.
38. Leow PC, Tian Q, Ong ZY, Yang Z and Ee PL: Antitumor activity of natural compounds, curcumin and PKF118-310, as Wnt/-catenin antagonists against human osteosarcoma cells. Invest New Drugs 28: 766-782, 2010.
39. Subramaniam D, Ponnurangam S, Ramamoorthy P, Standling D, Battafarano RJ, Anant S and Sharma P: Curcumin induces cell death in esophageal cancer cells through modulating notch signaling. PloS One 7: e30590, 2012.
40. Elamin MH, Shinwari Z, Hendrayani SF, Al-Hindi H, Al-Shail E, Khafaga Y, Al-Kofide A and Aboussekhra A: Curcumin inhibits the Sonic Hedgehog signaling pathway and triggers apoptosis in medulloblastoma cells. Mol Carcinog 49: 302-314, 2010.
41. Alexandrow MG, Song LJ, Altiok S, Haura EB and Kumar NB: Curcumin: a novel STAT3 pathway inhibitor for chemoprevention of lung cancer. Eur J Cancer Prev 21(5): 407-412, 2012.
42. Chiu SS, Liu E, Majeed M, Vishwanatha JK, Ranjan AP, Maitra A, Pramanik D, Smith JA and Helson L: Differential distribution of intravenous curcumin formulations in the rat brain. Anticancer Res 31(3): 907-911, 2011.
43. Priyadarsini KI: The chemistry of curcumin: from extraction to therapeutic agent. Molecules 19: 20091-20112, 2014.
44. Gao X, Deeb D, Jiang H, Liu YB, Dulchavsky AS and Gautam SC: Curcumin differentially sensitizes malignant glioma cells to TRAIL/APO2L-mediated apoptosis through activation of procaspases and release of cytochrome c from mitochondria. J Exp Ther Oncol 5: 39-48, 2005.
45. Kim SY, Jung SH and Kim HS. Curcumin is a potent broad spectrum inhibitor of matrix metalloproteinase gene expression in human astroglioma cells. Biochem Biophys Res Commun 337: 510-516, 2005.
46. Nagai S, Kurimoto M, Washiyama K, Hirashima Y, Kumanishi Y and Endo S: Inhibition of cellular proliferation and induction of apoptosis by curcumin in human malignant astrocytoma cell lines. J Neurooncol 74: 105-111, 2005.
47. Woo MS, Jung SH, Kim SY, Hyun JW, Ko KH, Kim WK, Kim HS: Curcumin suppresses phorbol ester-induced matrix metalloproteinase-9 expression by inhibiting the PKC to MAPK signaling pathways in human astroglioma cells. Biochem Biophys Res Commun 335: 1017-1025, 2005.
48. Belkaid A, Copland IB, Massillon D and Annabi B: Silencing of the human microsomal glucose-6-phosphate translocase induces glioma cell death: potential new anticancer target for curcumin. FEBS Lett 580: 3746-3752, 2006.
49. Karmakar S, Banik NL, Patel SJ and Ray SK: Curcumin activated both receptor mediated and mitochondria-mediated proteolytic pathways for apoptosis in human glioblastoma T98G cells. Neurosci Lett 407: 53-58, 2006.
50. Aoki H, Takada Y, Kondo S, Sawaya R, Aggarwal BB and Kondo Y: Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: role of Akt and extracellular signal-regulated kinase signaling pathways. Mol Pharmacol 72: 29-39, 2007.
51. Choi BH, Kim CG, Bae Y, Lim Y, Lee YH, and Shin SY: p21WAF1/CIP1 expression by curcumin in U-87MG human glioma cells: role of early growth response-1 expression. Cancer Res 68: 1369-1377, 2008.
52. Senft C, Polacin M, Priester M, Seifer V, Kogel D and Weissenberger J: The nontoxic natural compound curcumin exerts antiproliferative, antimigratory, and anti-invasive properties against malignant gliomas. Cancer 10: 491-498, 2010.
53. Dhandapani KM, Mahesh VB and Brann DW: Curcumin suppresses growth and chemoresistance of human glioblastoma cells via AP-1 and NFB transcription factors. J Neurochem 102: 522-538, 2007.
54. Zanotto-Filho A, Braganhol E, Edelweiss MI, Behr GA, Zanin R, Schroder R, Simoes-Pires A, Battastini AM and Moreira JC: The curry spice curcumin selectively inhibits cancer cells growth in vitro and in preclinical model of glioblastoma. J Nutr Biochem 23(6): 591-601, 2012.
55. Perry MC, Demeule M, Regina A, Moumdjian R and Beliveau R: Curcumin inhibits tumor growth and angiogenesis in glioblastoma xenografts. Mol Nutr Food Res 54(8): 1192-1201, 2010.
56. Beier D, Schulz JB and Beier CP: Chemoresistance of glioblastoma cancer stem cells-much more complex than expected. Mol Cancer 10: 128, 2011.
57. Bleau AM, Hambardzumyan D, Ozawa, T, Fomchenko EI, Huse JT, Brennan CW and Holland EC: PTEN/PI3K/AKT pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 4: 226-235, 2009.
58. Schiffer D, Mellai M, Annovazzi L, Piazzi A, Monzeglio O and Caldera V: Glioblastoma cancer stem cells: basis for a functional hypothesis. Stem Cell Discov 2(3): 122-131, 2012.
59. Fong D, Yeh A, Naftalovich R, Choi TH and Chan MM: Curcumin inhibits the side population (SP) phenotype of the rat C6 glioma cell line: towards targeting of cancer stem cells with phytochemicals. Cancer Lett 293(1): 65-72, 2010.
60. Zhuang W, Long L, Zheng B, Ji W, Yang N, Zhang Q and Liang Z: Curcumin promotes differentiation of gliomainitiating cells by inducing autophagy. Cancer Sci 103(4): 684-690, 2012.
61. Ganta S and Amiji M: Coadministration of paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol Pharm 6: 928-939, 2009.
62. Bisht S, Mizuma M, Feldmann G, Ottenhof NA, Hong SM, Pramanik D, Chenna V, Karikari C, Sharma R, Goggins MG, Rudek MA, Ravi R, Maitra A and Maitra A: Systemic administration of polymeric nanoparticle-encapsulated curcumin (NanoCurc) blocks tumor growth and metastases in preclinical models of pancreatic cancer. Mol Cancer Ther 9: 2255-2264, 2010.
63. Helson L: Curcumin (diferoylmethane) delivery methods: a review. Biofactors 39: 21-26, 2013.
64. Sehedic D, Cikankowitz A, Hindre F, Davodeau F and Garcion E: Nanomedicine to overcome radioresistance in glioblastoma stem-like cells and surviving clones. Trends Pharmacol Sci 36(4): 236-225, 2015.
65. Zanotto-Filho A, Coradini K, Braganhol E, Schroder R, de Oliveira CM, SimoesPires A, Battastini AM, Pohlmann AR, Guterres SS, Forcelini CM, Beck RC and Moreira JC: Curcumin-loaded lipid-core nanocapsules as a strategy to improve pharmacological efficacy of curcumin in glioblastoma treatment. Eur J Pharm Biopharm 83(2): 156-167, 2013.
66. Lim KJ, Maitra A, Bisht S, Eberhart C and Bar E: Using nanocurcumin to treat medulloblastoma and glioblastoma. Cancer Res 70: 4440, 2010.
67. Langone P, Debata PR, Inigo Jdel R, Dolai S, Mukherjee S, Halat P, Mastroianni K, Curcio GM, Castellanos MR, Raja K and Banerjee P: Coupling to a glioblastoma directed antibody potentiates antitumor activity of curcumin. Int J Cancer 135(3): 7109, 2014.
68. Ramachandran C, Nair SM, Escalon E and Melnick SJ: Potentiation of etoposide and temozolomide cytotoxicity by curcumin and turmeric force in brain tumor cell lines. J Complement Integr Med 9: Article 20, 2012.
69. Yin H , Zhou Y, Wen C , Zhou C , Zhang W , Hu X , Wang L , You C and Shao J: Curcumin sensitizes glioblastoma to temozolomide by simultaneously generating ROS and disrupting AKT/mTOR signaling. Oncol Rep 32(4): 1610-1616, 2014.
70. Zanotto-Filho A, Braganhol E, Edelweiss MI, Behr GA, Zanin R, Schroder R, Simoes-Pires A, Battastini AM and Moreira JC: The curry spice curcumin selectively inhibits cancer cells growth in vitro and in preclinical model of glioblastoma. J Nutr Biochem 23(6): 591-601, 2012.
71. Wu H, Liu Q, Cai T, Chen YD and Wang ZF: Induction of microRNA-146a is involved in curcumin-mediated enhancement of temozolomide cytotoxicity against human glioblastoma. Mol Med Rep 12(4): 5461-5466, 2015.
72. Hossain MM, Banik NK and Ray SK: Synergistic anticancer mechanisms of curcumin and paclitaxel for growth inhibition of human brain tumor stem cells and LN18 and U138-MG cells. Neurochem Int 61: 1102-111, 2012.
73. Lim KJ, Bisht S, Bar EE, Maitra A and Eberhart CG: A polymeric nanoparticle formulation of curcumin inhibits growth, clonogenicity and stem-like fraction in malignant brain tumors. Cancer Biol Ther 11: 464-473, 2011.
74. Sordillo PP and Helson L: Curcumin and cancer stem cells: curcumin has asymmetrical effects on cancer and normal stem cells. Anticancer Res 35: 599-614, 2015.
75. Almanaa TN, Geusz ME and Jamasbi RJ: Effects of curcumin on stem-like cells in human esophageal squamous carcinoma cell lines. BMC Compl Altern Med 12: 195, 2012.
76. Batth BK, Tripathi R and Srinivas UK: Curcumin-induced differentiation of mouse embryonal carcinoma PCC4 cells. Differentiation 68: 133-140, 2001.
77. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, Wong H, Rosen J and Chang JC: Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100: 672-679, 2008.
78. Moussavi M, Assi K, Gomez-Munoz A and Salh B: Curcumin mediates ceramide generation via the de novo pathway in colon cancer cells. Carcinogenesis 27(8): 1636-44, 2006.
79. Grammatikos G, Teichgraber V, Carpinteiro A, Trarbach T, Weller M, Hengge UR and Gulbins E: Overexpression of acid sphingomyelinase sensitizes glioma cells to chemotherapy. Antioxid Redox Signal 9: 1449-1456, 2007.
80. Hara S, Nakashima S, Kiyono T, Sawada M, Yoshimura S, Iwama T, Banno Y, Shinoda J and Sakai N: p53-Independent ceramide formation in human glioma cells during gammaradiation-induced apoptosis. Cell Death Differ 11: 853-861, 2004.
81. Riboni L, Campanella R, Bassi R, Villani R, Gaini SM, Martinelli-Boneschi F, Viani P and Tettamanti G: Ceramide levels are inversely associated with malignant progression of human glial tumors. Glia 39: 105-113, 2002.
82. Giussani P, Bassi R, Anelli V, Brioschi L, De Zen F, Riccitelli E, Caroli M, Campanella R, Gaini SM, Viani P and Riboni L: Glucosylceramide synthase protects glioblastoma cells against autophagic and apoptotic death induced by temozolomide and Paclitaxel. Cancer Invest 30: 27-37, 2012.
83. Manago A, Becker KA, Carpinteiro A, Wilker B, Soddemann M, Seitz AP, Edwards MJ, Grassme H, Szabo I and Gulbins E: Pseudomonas aeruginosa pyocyanin induces neutrophil death via mitochondrial reactive oxygen species and mitochondrial acid sphingomyelinase. Antioxid Redox Signal 22: 1097-1110, 2015.
84. Hatanaka Y, Fujii J, Fukutomi T, Watanabe T, Che W, Sanada Y, Igarashi Y and Taniguchi N: Reactive oxygen species enhances the induction of inducible nitric oxide synthase by sphingomyelinase in RAW264.7 cells. Biochem Biophs Acta 1393: 203-210, 1998.
85. Castillo SS, Levy M, Thaikoottathil JV and Goldkorn T: Reactive nitrogen and oxygen species activate different sphingomyelinases to induce apoptosis in airway epithelial cells. Exp Cell Res 313: 2680-2686, 2007.